Want to see BIAF full AI Analyst Report?
BIAF Stock Chart & Stats
$1.29
-$0.03(-2.64%)
At close: 4:00 PM EST
$1.29
-$0.03(-2.64%)
Day’s Range― - ―
52-Week Range$0.69 - $13.52
Previous CloseN/A
Volume17.91K
Average Volume (3M)5.91M
Market Cap
$5.21M
Enterprise Value$2.06M
Total Cash (Recent Filing)$3.10M
Total Debt (Recent Filing)$1.38M
Price to Earnings (P/E)―
Beta-3.57
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.47
Shares Outstanding6,283,061
10 Day Avg. Volume6,249,809
30 Day Avg. Volume5,911,951
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.28
Price to Sales (P/S)0.33
P/FCF Ratio-0.22
Enterprise Value/Market Cap0.39
Enterprise Value/Revenue0.36
Enterprise Value/Gross Profit1.64
Enterprise Value/Ebitda-0.13
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-8.1
Revenue Forecast (FY)$7.31M
Bulls Say, Bears Say
Bulls Say
Commercialization StrategyCyPath testing was up year-over-year with record testing volume in both June and July 2025, reflecting an accelerated commercialization strategy and increased clinical adoption.
Market ExpansionThe company is selling tests in several other states through referrals and word-of-mouth even before a broader commercial rollout.
Bears Say
Coverage SuspensionEffective immediately, Maxim Group is suspending coverage of bioAffinity Technologies, Inc. due to a reallocation of resources.
Financial PerformanceThe company's capital constraints remain a concern; therefore, analysts maintain a Hold rating as they believe the risk/reward is balanced.
Profitability ConcernsThe inability to operate profitably and the need to raise additional capital gives analysts pause, leading to a recommendation not to purchase shares at this time.
bioAffinity Technologies, Inc. News
BIAF FAQ
What was bioAffinity Technologies, Inc.’s price range in the past 12 months?
bioAffinity Technologies, Inc. lowest stock price was $0.69 and its highest was $13.52 in the past 12 months.
What is bioAffinity Technologies, Inc.’s market cap?
bioAffinity Technologies, Inc.’s market cap is $5.21M.
When is bioAffinity Technologies, Inc.’s upcoming earnings report date?
bioAffinity Technologies, Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 46 days.
How were bioAffinity Technologies, Inc.’s earnings last quarter?
bioAffinity Technologies, Inc. released its earnings results on May 08, 2026. The company reported -$0.81 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.81.
Is bioAffinity Technologies, Inc. overvalued?
According to Wall Street analysts bioAffinity Technologies, Inc.’s price is currently Overvalued.
Does bioAffinity Technologies, Inc. pay dividends?
bioAffinity Technologies, Inc. does not currently pay dividends.
What is bioAffinity Technologies, Inc.’s EPS estimate?
bioAffinity Technologies, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does bioAffinity Technologies, Inc. have?
bioAffinity Technologies, Inc. has 6,283,061 shares outstanding.
What happened to bioAffinity Technologies, Inc.’s price movement after its last earnings report?
bioAffinity Technologies, Inc. reported an EPS of -$0.81 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.245%.
Which hedge fund is a major shareholder of bioAffinity Technologies, Inc.?
Currently, no hedge funds are holding shares in BIAF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
bioAffinity Technologies, Inc.
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.
Technical Analysis
ENDRA Life Sciences
―
Intelligent Bio Solutions
―
iSpecimen
―
BioNexus Gene Lab Corp
―
―
Ownership Overview
―
Insiders
1.68% Mutual Funds
0.69% Other Institutional Investors
96.74% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---